2014年2月5日
临床研究计划提供了芝加哥的尖端精密药物基因组肿瘤分析
与# 65279；芝加哥–；T他罗伯特H. Lurie
西北大学综合癌症中心，在
与之合作西北
药物治疗发展研究所（nmdti）和西北
纪念医院，已推出了新的研究计划，西北
肿瘤组（序列、评估、治疗），提供更加个性化、精准
肿瘤与基因组学结合的癌症患者的药物选择。本程序
最初将重点放在任何类型的癌症患者没有反应
传统疗法。 &ldquo；西北—将帮助建立芝加哥作为一个国家，癌症，”在精密医学国际领袖；说莱昂尼达斯Platanias，MD，PhD，Lurie癌症中心的主任。&ldquo；这是第一次在芝加哥的癌症治疗将在全面提供，使用分子定义的基因组目标作为确定治疗方案包括新的早期基础学科课程—期临床试验。”； Onco—SET personalizes cancer care for each patient by sequencing the individual genetic profile of their tumors –； known as genomic profiling –； and evaluating the results to provide the treatments or clinical trials that will benefit them most. Some of these approaches include site—agnostic, pathway—driven治疗，以治疗为目标的一种类型的癌症特异性基因异常，并将其应用于治疗一种cancerif相同遗传异常。 “As part of our work with Onco—SET, we are also planning to initiate a pilot program of site—agnostic, pathway—driven tumor clinics,” added Platanias.
To evaluate and discuss the best treatment options for each patient, Onco—SET created the Lurie Cancer Center’s Molecular Tumor Board, which brings together a group of experts to review every tumor’s genomic profile. The board is comprised of a wide spectrum of cancer specialists, including pathologists, medical, surgical and radiation oncologists, as well as cancer geneticists, genome biologists, molecular scientists,bioethicistsand bioinformaticists. Treatment options made available to the Molecular Tumor Board through Onco—SET include noveltherapies from a variety of early—阶段临床试验。 “Onco—SET will provide the environment and infrastructure in which we can deliver personalized cancer treatment for patients who currently have very limited options, while accelerating our other research focused on developing novel individually tailored agents,” said Francis Giles, MD, deputy director of the Lurie Cancer Center, co—chair of the Molecular Tumor Board and director of NMDTI. “We will be able to learn more about which genomic targets are most important to effectively treat cancer and identify potential targets for which no drugs may currently exist.” By offering cancer patients care within Onco—SET, the program is also expanding the Lurie Cancer Center’s pre—clinical research by collecting and analyzing detailed data from each patient’s tumor genomic profiles. The information collected will allow Northwestern Medicine researchers to identify new treatment patterns and important genomic pathways to help develop novel approaches to cancer treatment. To learn more about Onco—SET call 1—855—82—NMDTI (1—855—826—6384). To learn more about the cancer care at the Lurie Cancer Center or schedule an appointment, visit cancer.northwestern.edu or call 312—695—0990.媒介接触：
布雷特昆斯
高级媒体关系副
312—926—2955
bcoons@nm.org
